Sponsors usually own their clinical trial data on paper, but ownership means little without access. Securing it requires contract terms that guarantee real-time access to study systems, scheduled data transfers in agreed formats, audit trails and metadata, cooperation when changing vendors and clear rules for archiving and retention at study end. The time to negotiate all of this is before the contract is signed, not when you need the data.
Why isn't ownership enough?
Data live in the CRO's systems: EDC, safety databases, trial master files and clinical trial management systems. If the contract doesn't specify how and when the sponsor gets access, the sponsor may wait weeks for exports, receive data in unexpected formats or face fees to retrieve its own information. That becomes acute during a CRO transition, a partnering deal or a regulatory inspection.
What access should sponsors have during the study?
Read-only access to EDC, the eTMF and relevant reports, for named sponsor staff.
Scheduled data transfers in agreed formats and at agreed intervals.
Safety data access consistent with the sponsor's responsibilities.
Operational data such as enrollment, site status and deviations through dashboards or reports.
Ad hoc requests with defined turnaround times.
What should transfers include?
The clinical data themselves, in an agreed structure, ideally aligned with CDISC standards. Metadata and data dictionaries. Audit trails showing who entered and changed what, and when. Query histories. Coding dictionaries and versions. Documentation of the database build and any changes. Without these, data are harder to use, defend or move.
What happens when you change CROs?
Define transition obligations in the original contract: cooperation, timelines, formats, fees and the transfer of documents, data and system access. Include requirements for knowledge transfer and the handover of the trial master file. Sponsors who negotiate these terms at the start rarely need to invoke them, but those who don't often regret it.
What about the end of the study?
Agree on database archiving, final data transfers, the transfer or archiving of the trial master file and how long the CRO will retain records on the sponsor's behalf. Confirm that archived data will remain readable and that the sponsor can access them for inspections, submissions and future analyses. Sponsors must keep essential records for the period required by regulation, and planning for that early prevents an expensive scramble later.
Should sponsors own their systems instead?
Sometimes. Licensing your own EDC or eTMF gives more control and makes CRO changes simpler, but adds cost and management work. Many emerging biotechs start with CRO systems and move toward owning some systems as their pipeline grows. Either way, contract terms for access and transfer remain essential.
How should you check your current contracts?
Review your master services agreement and work orders for data ownership, access, transfer formats, timing, fees, transition support, archiving and retention. Ask your CRO for a sample data transfer early in the study. If the answers are vague, fix them now, while the relationship is healthy.
Keep reading: Do You Need Your Own Clinical Systems?
